Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus (2018) Ott O, Schmidt M, Semrau S, Strnad V, Matzel KE, Schneider IHF, Raptis D, et al. Journal article Anti-tumor immune responses in primary and abscopal tumors differently depend on radiotherapy fractionation and immunotherapy modalities (2018) Rueckert M, Frey B, Fietkau R, Gaipl U Conference contribution Can local excision be safely recommended in patients with ypT0-2 rectal cancer after chemoradiotherapy? Clinicopathological results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 randomized phase 3 trials (2018) Von Den Gruen MJ, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Stroebel P, Sauer R, et al. Conference contribution Dose Reduction in the Swallowing Area by De-intensification of Radiotherapy in Patients with Head and Neck Cancer in the postoperative Situation - first Plan Analyzes of the DIREKHT Study (2018) Haderlein M, Speer S, Hecht M, Merten R, Scherl C, Semrau S, Ott O, Fietkau R Conference contribution Comparison of VMAT and IMRT in deep inspiration breath hold technique for left breast irradiation: Improved conformity and homogeneity versus sparing of organs at risk (2018) Karpf D, Sakka M, Metzger M, Grabenbauer G Conference contribution Volumetric assessment of paragangliomas of the head and neck following stereotactic radiotherapy (2018) Putz F, Weissmann T, Lettmaier S, Semrau S, Fietkau R Conference contribution The Role of local radical Therapy Approach in the metastatic Stage of Small Cell Lung Cancer (SCLC) (2018) Zoske H, Lettmaier S, Fietkau R, Putz F Conference contribution Tumor-specific Toxicity to malignant Melanoma Cells by the dual DNA-PK and mTOR Inhibitor CC115 in Combination with ionizing Radiation (2018) Burkel F, Jost T, Proebstle S, Hecht M, Fietkau R, Distel L Conference contribution Local recurrence of breast cancer: conventionally fractionated partial external beam re-irradiation with curative intention (2018) Janssen S, Rades D, Meyer A, Fahlbusch FB, Wildfang I, Meier A, Schild S, et al. Journal article Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy (2018) Hecht M, Gaipl U, Fietkau R Journal article